Postoperative Acute Kidney Injury (PO-AKI)
Conditions
Interventions
Control group (L group):Intravenous injection of isovolume normal saline
Lidocaine: 1.5 mg/kg intravenously.
Experimental group (L+E group):Esketamine 0.5 mg/kg intravenously
Lidocaine 1.5mg/kg intravenously.
Sponsors
Mianyang Central Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age>= 65 years old, gender is not limited; 2.ASA Grades II-III; 3.elective radical colorectal cancer resection; 4.Normal preoperative renal function (serum creatinine within the normal range); 5.Patients voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Those who are allergic to esketamine, lidocaine or other narcotic drugs; 2.Patients with severe cardiac, pulmonary, and hepatic insufficiency; 3.Those with a history of psychiatric illness or central nervous system disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To observe the effect of esketamine combined with lidocaine on the incidence of PO-AKI in colorectal cancer surgery patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| To observe the effect of esketamine combined with lidocaine on postoperative adverse reactions in patients undergoing colorectal cancer surgery; | — |
Countries
China
Contacts
Public ContactTan Shilian
Mianyang Central Hospital
Outcome results
None listed